Literature DB >> 25494859

Adolescent non-adherence reveals a genetic cause for diabetes.

D Carmody1, K L Lindauer1, R N Naylor1.   

Abstract

BACKGROUND: Glucokinase related maturity-onset diabetes of the young (GCK-MODY) is a form of monogenic diabetes characterized by mildly elevated fasting blood sugars and HbA(1c) typically ranging from 38 to 60 mmol/mol (5.6-7.6%). It is frequently unrecognized or misdiagnosed as Type 1 or Type 2 diabetes, resulting in unnecessary pharmacologic therapy. CASE REPORT: Two brothers were initially diagnosed with Type 1 diabetes mellitus. The brothers were maintained on a total daily insulin dose of 0.3-0.5 units/kg/day and had HbA(1c) values of 40-51 mmol/mol (5.8-6.8%) throughout childhood. After over 10 years of insulin treatment, the younger brother chose to discontinue his insulin therapy without informing his family or his clinician. Following cessation of insulin treatment, he did not experience any change in overall glycaemic control. Subsequent research-based genetic testing revealed a deleterious mutation in GCK in both brothers (p.Val182Met). The older brother subsequently discontinued insulin therapy and both have remained off all pharmacological therapy with good glycaemic control (HbA(1c) < 53 mmol/mol, < 7%) and no adverse complications. The family was advised to seek confirmatory genetic testing in the father and other relatives with hyperglycaemia.
CONCLUSION: The family described above exemplifies the rationale behind considering a genetic cause when evaluating every person with new-onset hyperglycaemia or those with atypical diabetes. The cost of genetic testing for the most common MODY causing genes may be offset by savings made in therapeutic costs. It is important that all clinicians supervising diabetes care recognize the cardinal features that distinguish GCK-MODY from other forms of diabetes.
© 2014 The Authors. Diabetic Medicine © 2014 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25494859      PMCID: PMC4640698          DOI: 10.1111/dme.12669

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  17 in total

1.  Trends in childhood type 1 diabetes incidence in Europe during 1989-2008: evidence of non-uniformity over time in rates of increase.

Authors:  C C Patterson; E Gyürüs; J Rosenbauer; O Cinek; A Neu; E Schober; R C Parslow; G Joner; J Svensson; C Castell; P J Bingley; E Schoenle; P Jarosz-Chobot; B Urbonaité; U Rothe; C Krzisnik; C Ionescu-Tirgoviste; I Weets; M Kocova; G Stipancic; M Samardzic; C E de Beaufort; A Green; G G Dahlquist; G Soltész
Journal:  Diabetologia       Date:  2012-05-26       Impact factor: 10.122

2.  Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus.

Authors:  N Vionnet; M Stoffel; J Takeda; K Yasuda; G I Bell; H Zouali; S Lesage; G Velho; F Iris; P Passa
Journal:  Nature       Date:  1992-04-23       Impact factor: 49.962

3.  The 0.1% of the population with glucokinase monogenic diabetes can be recognized by clinical characteristics in pregnancy: the Atlantic Diabetes in Pregnancy cohort.

Authors:  Ali J Chakera; Gill Spyer; Nicola Vincent; Sian Ellard; Andrew T Hattersley; Fidelma P Dunne
Journal:  Diabetes Care       Date:  2014-02-18       Impact factor: 19.112

4.  Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth.

Authors:  Catherine Pihoker; Lisa K Gilliam; Sian Ellard; Dana Dabelea; Cralen Davis; Lawrence M Dolan; Carla J Greenbaum; Giuseppina Imperatore; Jean M Lawrence; Santica M Marcovina; Elizabeth Mayer-Davis; Beatriz L Rodriguez; Andrea K Steck; Desmond E Williams; Andrew T Hattersley
Journal:  J Clin Endocrinol Metab       Date:  2013-06-14       Impact factor: 5.958

5.  A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus.

Authors:  S C Shah; J I Malone; N E Simpson
Journal:  N Engl J Med       Date:  1989-03-02       Impact factor: 91.245

6.  Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.

Authors:  Rachel E J Besser; Maggie H Shepherd; Timothy J McDonald; Beverley M Shields; Bridget A Knight; Sian Ellard; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2011-02       Impact factor: 19.112

Review 7.  MODY: history, genetics, pathophysiology, and clinical decision making.

Authors:  Stefan S Fajans; Graeme I Bell
Journal:  Diabetes Care       Date:  2011-08       Impact factor: 19.112

8.  Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications.

Authors:  Rochelle N Naylor; Priya M John; Aaron N Winn; David Carmody; Siri Atma W Greeley; Louis H Philipson; Graeme I Bell; Elbert S Huang
Journal:  Diabetes Care       Date:  2013-09-11       Impact factor: 19.112

9.  Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia.

Authors:  Anna M Steele; Beverley M Shields; Kirsty J Wensley; Kevin Colclough; Sian Ellard; Andrew T Hattersley
Journal:  JAMA       Date:  2014-01-15       Impact factor: 56.272

10.  Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia.

Authors:  Amanda Stride; Beverley Shields; Olivia Gill-Carey; Ali J Chakera; Kevin Colclough; Sian Ellard; Andrew T Hattersley
Journal:  Diabetologia       Date:  2013-10-04       Impact factor: 10.122

View more
  3 in total

1.  Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes.

Authors:  Maggie Shepherd; Beverley Shields; Suzanne Hammersley; Michelle Hudson; Timothy J McDonald; Kevin Colclough; Richard A Oram; Bridget Knight; Christopher Hyde; Julian Cox; Katherine Mallam; Christopher Moudiotis; Rebecca Smith; Barbara Fraser; Simon Robertson; Stephen Greene; Sian Ellard; Ewan R Pearson; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2016-06-06       Impact factor: 19.112

2.  Novel HNF1A gene mutation in maturity-onset diabetes of the young: A case report.

Authors:  Qian Xu; Cheng-Xia Kan; Ning-Ning Hou; Xiao-Dong Sun
Journal:  World J Clin Cases       Date:  2022-02-26       Impact factor: 1.337

3.  A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.

Authors:  Maggie H Shepherd; Beverley M Shields; Michelle Hudson; Ewan R Pearson; Christopher Hyde; Sian Ellard; Andrew T Hattersley; Kashyap A Patel
Journal:  Diabetologia       Date:  2018-09-18       Impact factor: 10.122

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.